Loading
A phase 2 trial of BO-112 in basal cell carcinoma, run by Highlight Therapeutics, active and no longer recruiting.
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT06422936 by Highlight Therapeutics, with 60 participants enrolled, started 2024-05-27 and due to reach its primary completion in 2026-06. Interventions recorded: BO-112.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/